If you have been reading about circadian clock and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-14. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
== Histology == The chief cells are organized as dense cords surrounding the capillaries in the parathyroid. Parathyroid chief cells make up the majority of the parathyroid gland along with adipocytes and oxyphil cells. Parathyroid chief cells have large amounts of organelles associated with protein synthesis. As in many endocrine organs, with age, more oxyphil cells appear in the parathyroid gland. Parathyroid tissue seems to have a low turn-over rate. Chief cells appear as a dark purple in an H&E stain, with the oxyphil cells staining as a lighter pink. They are polygonal in shape with a round nucleus. Chief cells spend most time inactive due to normal calcium level conditions. These inactive cells are classified as cuboidal. They have low levels of secretory granules, as opposed to active chief cells. These granules can contain acid phosphatase. Acid phosphatase is only found in larger secretory granules, 400 to 900 nm in diameter, and is less prevalent in smaller granules. This acid phosphatase is also present in the Golgi apparatus of the chief cell. However, the Golgi apparatus areas associated with parathyroid hormone packaging contained little or no acid phosphatase. The chief cells become active in response to low calcium in the blood. The low level is sensed by the calcium- sensing receptor. These active cells have a greater electron density than the inactive chief cells. The electron density is caused by the secretory granules. The chief cell is thought to have a clear cytoplasm.
They were moved to the Château de Facqueval in Modave, Belgium, where Hahn used the time to work on his memoirs and then, on 3 July, were flown to England. They arrived at Farm Hall, Godmanchester, near Cambridge, on 3 July. While they were there, all their conversations, indoors and out, were covertly recorded with hidden microphones. They were given British newspapers, which Hahn was able to read. He was greatly disturbed by their reports of the Potsdam Conference, where German territory was ceded to Poland and the USSR. In August 1945, the German scientists were informed of the atomic bombing of Hiroshima. Up to this point the scientists, except Harteck, were completely certain that their project was further advanced than any in other countries, and the Alsos Mission's chief scientist, Samuel Goudsmit, did nothing to correct this impression. Now the reason for their incarceration in Farm Hall suddenly became apparent. As they recovered from the shock of the announcement, they began to rationalise what had happened. Hahn noted that he was glad that they had not succeeded, and von Weizsäcker suggested that they should claim that they had not wanted to. They drafted a memorandum on the project, noting that fission was discovered by Hahn and Strassmann. The revelation that Nagasaki had been destroyed by a plutonium bomb came as another shock, as it meant that the Allies had not only been able to conduct uranium enrichment, but had mastered nuclear reactor technology as well. The memorandum became the first draft of a postwar apologia.
Stuart Wright, Dancer's Guide to Injuries of the Lower Extremity (New York: Cornwall Books, 1985), p. 14. Swischuk, Leornard E. "Doing the Splits: Heard A Pop--Cannot Walk." Pediatric Emergency Care 23.11 (2007): 842-3. Web. 8 Sep. 2010. <http://ovidsp.tx.ovid.com>.
=== Breast cancer === Docetaxel and paclitaxel have comparable efficacy metastatic breast cancer but paclitaxel has less severe side effects. Additionally, it has been noted that docetaxel is prone to cellular drug resistance via a variety of different mechanisms.
Sources: en.wikipedia.org
This exposes the diabetic foot to thermal or mechanical trauma, and to the late detection of infection processes or tissue breakdown; effects on foot morphology (deformities): due to most of the above alterations, a significant imbalance of peripheral musculature and soft tissue occurs in the foot, which seriously alters its morphology and determines the onset of foot deformities. Most common deformities of the diabetic foot are represented by a high longitudinal arch (rigid cavus foot), hammer toes, and hallux valgus. A completely different morphologic degeneration is represented by neuropathic arthropathy, whose analysis is not part of this discussion.
Striking deep into cities like Kyiv, Odessa, and Zaporizhzhia, self-targeting AI drones have misidentified or collided with civilian infrastructure—including business centers, energy grids, and medical centers—resulting in widespread non-combatant fatalities far from the active lines of contact.
=== Southeast Asia === Tofu is called tauhu in Malaysia and Singapore as well as tahu in Indonesia both from Hokkien tāu-hū; it is also known as taufu in Malaysia from Cantonese. Indonesia, Thailand, Malaysia, and the Philippines are major producers of tofu and have plants in many municipalities.
In some cases soon after the operation, there were indeed noticeable positive changes in appearance and behavior (with a rapid senility of the body soon following). There were many messages about wonderful results of the operations that, apparently, were false advertising of unscrupulous doctors. But numerous failures became apparent, for which the method was sharply criticized and banned. Serge Voronoff and some other doctors, who claimed producing wonderful results after the operations, got bad reputation. However, despite the failure in the main direction, the conducted research led to the emergence of allotransplantation and xenotransplantation directions in surgery, brought significant knowledge about the effect of sex hormones on the body, stimulated their study. It may be just a coincidence but in 1929–33 several varieties of estrogen were discovered, and testosterone was isolated in 1935. Also these experiments formed the basis for several works of public culture (for example, Heart of a Dog by Mikhail Bulgakov, The Adventure of the Creeping Man from the series about Sherlock Holmes, a song Monkey-Doodle-Doo of Irving Berlin). 1926–1928 Experiments on rejuvenation by blood transfusion, conducted by Alexander Bogdanov in the world's first Institute for Blood Transfusion especially created for that purpose. Bogdanov himself died during one of the experiments, because at that time little was known about the factors of blood compatibility of different people. The institute, having undergone several renames, exists and is still actively working.
=== John-Daniel Stern === John-Daniel "JD" Stern (Adain Bradley) is Harper's estranged twin brother, who disappeared from her life when the two were teenagers. In series 2, Harper tracks down her brother to Berlin, where he works as a line cook. The two spend the night at a club, and the next morning, JD relapses on his meth addiction. The two have a vicious argument over their childhood growing up with an abusive mother; JD reveals he ran away in part due to Harper exacerbating the pressure their mother put on him to be a star tennis player, but Harper maintains that she too escaped a traumatic upbringing. Harper begs JD to come home with her, but rebuffs her, branding his sister a selfish narcissist who was complicit in the abuse he suffered. Harper is left deeply shaken by the encounter. In series 4, JD calls Harper to tell her that their mother died in a freak accident, having fallen down the stairs while collecting an Amazon delivery. Harper struggles to grieve her mother's death given her traumatic childhood, as well as her preoccupation with her work.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.